Company Info

We keep challenging – for living brilliant future together

Dec 2006
Business Started as JapanBridge
Jun 2007
Cooperation Agreement with Kyowa Hakko Kogyo Co.,
Ltd.(currently, Kyowa Hakko kirin Co., Ltd.) in oncology
Jan 2008
Establishment of Medical & Scientific Advisory Board
May 2008
License Agreement with ProStrakan for exclusive rights
to Sancuso® in Japan, China, and other Asian territories
Sep 2008
Company name changed to Solasia Pharma K.K.
Apr 2009
Corporate office moved to Shiodome Building (Tokyo)
Jul 2009
Completion of SP-01 (Sancuso®) Japanese Phase I
study
Feb 2010
License Agreement with Kyowa Hakko Kirin Co., Ltd. for
the sublicense of Sancuso® in Taiwan, Hong Kong,
Singapore & Malaysia
Mar 2011
License Agreement with ZIOPHARM Oncology Inc. for
exclusive rights to darinaparsin in Japan, China, and
other Asian territories
Dec 2011
Open Beijing Representative Office in China
Jan 2013
Open Shanghai Office in China
Nov 2013
Completion of SP-01 (Sancuso®) clinical
pharmacological study targeting Chinese healthy adult
patient in China
Dec 2013
Completion of subject enrollment in SP-02L
(darinaparsin injection) Phase I study targeting Korean
cancer patient
May 2014
Completion of SP-01 (Sancuso®) Phase III study
targeting cancer patient with chemotherapy-induced
nausea and vomiting in China
Jun 2014
Filing of New Drug Application (NDA) SP-01 (Sancuso®)
in China
Jul 2014
License Agreement with ZIOPHARM Oncology Inc. for
global license and collaboration for darinaparsin
Aug 2014
Completion of subject enrollment in SP-02L
(darinaparsin injection) Phase I study targeting
Japanese cancer patient
Dec 2014
Establishment of the subsidiary in Shanghai
Jan 2015
License Agreement with Meiji Seika Pharma for the
development and commercialization of darinaparsin
(intravenous formulation) in Japan.
Mar 2015
License and Distribution Agreement with Camurus for
exclusive license of episil® in Japan and China
Nov 2015
License Agreement with Lee’s Pharmaceutical (HK)
Limited for the commercialization of Sancuso® in China
excluding Beijing, Shanghai, Guangzhou, Hong Kong,
Macau and Taiwan.
Mar 2016
Asian Multinational Phase II study of SP-02L
(darinaparsin injection) started
May 2016
Filing of New Medical Device Application (NMDA) for
episil® in China
Oct 2016
Filing of New Medical Device Application (NMDA) for
episil® in Japan
Nov 2016
License and Collaboration Agreement With Meiji Seika
Pharma for episil® in Japan
Feb 2017
License Agreement with Lee's Pharmaceutical (HK) Limited for the commericalization of episil® in China excluding Beijing, Shanghai, Guangzhou and Taiwan
Mar 2017
Solasia listed it's shares to Tokyo Exchange Mothers

Page Top

SELECT YOUR LANGUAGE